MX377396B - Compuestos de azapiridona y usos de los mismos. - Google Patents

Compuestos de azapiridona y usos de los mismos.

Info

Publication number
MX377396B
MX377396B MX2016003199A MX2016003199A MX377396B MX 377396 B MX377396 B MX 377396B MX 2016003199 A MX2016003199 A MX 2016003199A MX 2016003199 A MX2016003199 A MX 2016003199A MX 377396 B MX377396 B MX 377396B
Authority
MX
Mexico
Prior art keywords
compounds
aza
azapiridone
pyridone compounds
infection
Prior art date
Application number
MX2016003199A
Other languages
English (en)
Other versions
MX2016003199A (es
Inventor
Antitsa Dimitrova Stoycheva
David Bernard Smith
Leonid Beigelman
Robert Than Hendricks
Original Assignee
Janssen Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biopharma Inc filed Critical Janssen Biopharma Inc
Publication of MX2016003199A publication Critical patent/MX2016003199A/es
Publication of MX377396B publication Critical patent/MX377396B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen en la presente compuestos de azapiridona, composiciones farmacéuticas que incluyen uno o más compuestos de azapiridona, y métodos de síntesis de los mismos. También se describen en la presente métodos para mejorar y/o tratar una enfermedad y/o una condición, incluyendo una infección por ortomixovirus, con un compuesto de azapiridona. Los ejemplos de una infección viral por ortomixovirus incluyen infección por influenza.
MX2016003199A 2013-09-12 2014-09-10 Compuestos de azapiridona y usos de los mismos. MX377396B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361877151P 2013-09-12 2013-09-12
US201462011784P 2014-06-13 2014-06-13
US201462031673P 2014-07-31 2014-07-31
PCT/US2014/055012 WO2015038655A1 (en) 2013-09-12 2014-09-10 Aza-pyridone compounds and uses thereof

Publications (2)

Publication Number Publication Date
MX2016003199A MX2016003199A (es) 2016-06-02
MX377396B true MX377396B (es) 2025-03-10

Family

ID=52626171

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016003199A MX377396B (es) 2013-09-12 2014-09-10 Compuestos de azapiridona y usos de los mismos.
MX2020012132A MX2020012132A (es) 2013-09-12 2016-03-10 Compuestos de azapiridona y usos de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020012132A MX2020012132A (es) 2013-09-12 2016-03-10 Compuestos de azapiridona y usos de los mismos.

Country Status (18)

Country Link
US (5) US9328119B2 (es)
EP (2) EP3030566B1 (es)
JP (1) JP6448647B2 (es)
KR (2) KR102468319B1 (es)
CN (1) CN105764904B (es)
AU (2) AU2014318832B2 (es)
BR (1) BR112016005270B1 (es)
CA (1) CA2923075C (es)
CL (1) CL2016000539A1 (es)
EA (1) EA037949B1 (es)
ES (1) ES2821394T3 (es)
IL (2) IL244432B (es)
MX (2) MX377396B (es)
PE (1) PE20160661A1 (es)
PH (1) PH12016500486A1 (es)
TW (1) TWI652269B (es)
UA (1) UA121199C2 (es)
WO (1) WO2015038655A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010262905B2 (en) 2009-06-17 2015-04-16 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
JP6284547B2 (ja) 2012-12-21 2018-02-28 アリオス バイオファーマ インク． 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体
KR102286860B1 (ko) 2013-09-12 2021-08-05 얀센 바이오파마, 인코퍼레이트. 피리다지논 화합물 및 이의 용도
JP6448647B2 (ja) 2013-09-12 2019-01-09 アリオス バイオファーマ インク． アザ−ピリドン化合物およびその用途
MX383931B (es) 2015-03-11 2025-03-14 Janssen Biopharma Inc Compuestos de aza-piridona y usos de estos.
PL3290424T3 (pl) 2015-04-28 2023-05-08 Shionogi & Co., Ltd Podstawione policykliczne pochodne pirydonu i ich prolek
AU2016256125B9 (en) 2015-04-28 2020-02-20 Shionogi And Co., Ltd. Substituted polycyclic pyridone derivative and prodrug thereof
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
TW201726678A (zh) 2015-10-30 2017-08-01 赫孚孟拉羅股份公司 嘧啶酮衍生物及其於治療、改善或預防病毒性疾病之用途
CR20180356A (es) 2015-12-15 2018-08-22 Shionogi & Co Un medicamento caracterizado por combinar un inhibidor de la endonucleasa cap-dependiente del virus de la influenza y un fármaco anti-influenza
US10858366B2 (en) 2016-03-08 2020-12-08 Novartis Ag Tricyclic compounds useful to treat orthomyxovirus infections
US10183945B2 (en) 2016-03-10 2019-01-22 Alios Biopharma, Inc. Method of preparing AZA-pyridone compounds
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017223231A1 (en) 2016-06-21 2017-12-28 Alios Biopharma, Inc. (s)-8-(benzhydryl )-6-isopropyl-3,5-dioxo- 5, 6,7,8,-tetrahydro-3h-pyrazino-[1,2-b]pyridazin-yl-isobutyrate antiviral agent for use in treating influenza
KR20190007517A (ko) 2016-08-10 2019-01-22 시오노기세야쿠 가부시키가이샤 치환된 다환성 피리돈 유도체 및 그의 프로드러그를 함유하는 의약 조성물
JOP20170169A1 (ar) * 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
CN118440096A (zh) 2017-06-20 2024-08-06 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
KR102477187B1 (ko) * 2018-01-17 2022-12-12 장시 카이시 파마슈티컬 테크놀로지 컴퍼니 리미티드 피리돈 유도체, 이의 입체 이성질체 및 항인플루엔자 바이러스 약물로서의 응용
US11629149B2 (en) 2018-02-28 2023-04-18 Novartis Ag 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza
CN113286793B (zh) * 2018-09-10 2024-04-05 共结晶制药公司 吡咯并吡嗪和吡啶并三嗪类流感病毒复制抑制剂
US12398103B2 (en) 2020-03-20 2025-08-26 Atux Iskay Llc 3-diarylmethylenes and uses thereof
KR20230121063A (ko) 2020-12-14 2023-08-17 더 스쿨 코포레이션 칸사이 유니버시티 전기 화학 디바이스용 전극 및 비수 전해질 이차전지
CN117126044B (zh) * 2023-04-12 2024-01-26 延边大学 一种微波辅助的甲基酮类化合物的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM354694A0 (en) * 1994-01-27 1994-02-17 Biota Scientific Management Pty Ltd Chemical compounds
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
CN100357284C (zh) * 2003-09-11 2007-12-26 浙江海正药业股份有限公司 抗流感病毒化合物及其制备方法和用途
CA2557926A1 (en) 2004-03-09 2005-09-22 Monica Donghi Hiv integrase inhibitors
JP4790703B2 (ja) 2004-04-07 2011-10-12 武田薬品工業株式会社 環式化合物
WO2005099699A1 (en) 2004-04-07 2005-10-27 Sepracor Inc. Combination of (s)-amlodipine and a beta-blocker, and methods for reducing hypertension
CA2578789A1 (en) 2004-09-03 2006-03-16 Celgene Corporation Substituted heterocyclic compounds and uses thereof
AR057623A1 (es) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
CN101340902B (zh) * 2005-11-28 2011-01-26 奥加生物药业（香港）有限公司 用半胱胺化合物处理病毒感染的材料和方法
FR2909090B1 (fr) 2006-11-23 2009-01-09 Sanofi Aventis Sa Derives de 2,5-dihydro-3h-pyrazolo[4,3-c]pyridazin-3-one substitues,leur preparation et leur application en therapeutique.
WO2008077188A1 (en) 2006-12-22 2008-07-03 Avexa Limited Bicyclic pyrimidinones and uses thereof
FR2921505B1 (fr) 2007-09-25 2014-01-31 Alstom Transport Sa Dispositif de communication radioelectrique
JP2009096991A (ja) 2007-09-27 2009-05-07 Fujifilm Corp 硬化性組成物、画像形成材料及び平版印刷版原版
WO2009053799A1 (en) 2007-10-24 2009-04-30 Glenmark Pharmaceuticals, S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
EP2719700A1 (en) 2008-01-09 2014-04-16 Amura Therapeutics Limited Tetrahydrofuro(3,2-b)pyrrol-3-one derivatives as inhibitors of cysteine proteinases
NZ593110A (en) 2008-12-09 2013-06-28 Gilead Sciences Inc pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
WO2010080864A1 (en) 2009-01-12 2010-07-15 Array Biopharma Inc. Piperidine-containing compounds and use thereof
BRPI1008498B8 (pt) 2009-02-05 2021-05-25 Takeda Pharmaceuticals Co compostos de piridazinona úteis como inibidores da fosfodiesterase 10a, composição farmacêutica, e, uso de um composto
WO2010096338A1 (en) 2009-02-23 2010-08-26 Merck Sharp & Dohme Corp. PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
TW201038572A (en) 2009-03-25 2010-11-01 Gruenenthal Gmbh Substituted spiro-amide compounds
WO2010110231A1 (ja) 2009-03-26 2010-09-30 塩野義製薬株式会社 置換された３－ヒドロキシ－４－ピリドン誘導体
TWI518084B (zh) * 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
WO2010138419A2 (en) * 2009-05-23 2010-12-02 Obio Pharmaceutical (H.K.) Ltd. Materials and methods for treating viral infections
PL2444400T3 (pl) * 2009-06-15 2018-08-31 Shionogi & Co., Ltd. Podstawiona policykliczna pochodna karbamoilopirydonowa
US8383638B2 (en) 2009-12-21 2013-02-26 Merck Sharp & Dohme Aminobenzoquinazolinone M1 receptor positive allosteric modulators
SG183484A1 (en) * 2010-02-26 2012-09-27 Japan Tobacco Inc 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
EP2593107A1 (en) 2010-07-12 2013-05-22 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
HRP20181250T1 (hr) 2010-09-24 2018-10-05 Shionogi & Co., Ltd. Predlijek iz supstituiranog policikličkog derivata karbamoilpiridona
SG11201401082XA (en) 2011-09-30 2014-04-28 Kineta Inc Anti-viral compounds
SG11201503946UA (en) 2013-01-08 2015-09-29 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
JP6448647B2 (ja) 2013-09-12 2019-01-09 アリオス バイオファーマ インク． アザ−ピリドン化合物およびその用途
KR102286860B1 (ko) 2013-09-12 2021-08-05 얀센 바이오파마, 인코퍼레이트. 피리다지논 화합물 및 이의 용도
CR20160557A (es) 2014-05-29 2017-01-20 Glaxosmithkline Ip Dev Ltd Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2
MX383931B (es) * 2015-03-11 2025-03-14 Janssen Biopharma Inc Compuestos de aza-piridona y usos de estos.
US10183945B2 (en) 2016-03-10 2019-01-22 Alios Biopharma, Inc. Method of preparing AZA-pyridone compounds
WO2017223231A1 (en) 2016-06-21 2017-12-28 Alios Biopharma, Inc. (s)-8-(benzhydryl )-6-isopropyl-3,5-dioxo- 5, 6,7,8,-tetrahydro-3h-pyrazino-[1,2-b]pyridazin-yl-isobutyrate antiviral agent for use in treating influenza
JOP20170169A1 (ar) * 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو

Also Published As

Publication number Publication date
AU2019201403A1 (en) 2019-03-21
US10251882B2 (en) 2019-04-09
HK1225715A1 (en) 2017-09-15
KR102323515B1 (ko) 2021-11-05
CN105764904B (zh) 2020-02-11
NZ717591A (en) 2021-10-29
PH12016500486A1 (en) 2016-05-16
AU2014318832B2 (en) 2018-11-29
CA2923075C (en) 2022-07-26
US20190314373A1 (en) 2019-10-17
CN105764904A (zh) 2016-07-13
EA037949B1 (ru) 2021-06-10
ES2821394T8 (es) 2021-05-12
US20200030328A1 (en) 2020-01-30
ES2821394T3 (es) 2021-04-26
EA201690372A1 (ru) 2016-08-31
KR20210135359A (ko) 2021-11-12
BR112016005270B1 (pt) 2022-11-01
KR102468319B1 (ko) 2022-11-16
AU2014318832A1 (en) 2016-04-28
TW201542553A (zh) 2015-11-16
WO2015038655A1 (en) 2015-03-19
KR20160052715A (ko) 2016-05-12
IL244432A0 (en) 2016-04-21
IL274355A (en) 2020-06-30
EP3030566A1 (en) 2016-06-15
EP3030566A4 (en) 2017-03-22
EP3030566B1 (en) 2020-07-08
MX2020012132A (es) 2021-01-29
CL2016000539A1 (es) 2016-09-02
IL274355B (en) 2021-02-28
MX2016003199A (es) 2016-06-02
EP3778603A1 (en) 2021-02-17
US20210186969A1 (en) 2021-06-24
CA2923075A1 (en) 2015-03-19
AU2019201403B2 (en) 2021-01-21
JP2016530314A (ja) 2016-09-29
US10702523B2 (en) 2020-07-07
US10980805B2 (en) 2021-04-20
UA121199C2 (uk) 2020-04-27
US9328119B2 (en) 2016-05-03
TWI652269B (zh) 2019-03-01
PE20160661A1 (es) 2016-08-05
US20160228438A1 (en) 2016-08-11
JP6448647B2 (ja) 2019-01-09
IL244432B (en) 2020-05-31
US20150072982A1 (en) 2015-03-12
BR112016005270A2 (pt) 2017-12-12

Similar Documents

Publication Publication Date Title
MX2020012132A (es) Compuestos de azapiridona y usos de los mismos.
PH12016500492A1 (en) Pyridazinone compounds and uses thereof
MX2020006150A (es) Composiciones que comprenden polirribonucleotidos circulares y usos de las mismas.
MX383931B (es) Compuestos de aza-piridona y usos de estos.
MX390014B (es) Compuestos de dinucleótidos cíclicos y métodos de uso.
BR112018003812A2 (pt) compostos de heteroarila como inibidores de irak e usos dos mesmos
EA201790630A1 (ru) Способы получения рибозидов
MX2016004340A (es) Compuestos heterociclicos y usos de los mismos.
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
MX2015011529A (es) Reordenamiento del virus de infuenza b.
BR112017014970A2 (pt) macrociclos de piridazinona como inibidores de irak e usos dos mesmos
MX2023006416A (es) Anticuerpos, usos y metodos.
MX2015012833A (es) Composiciones antibioticas de ceftolozano.
BR112017028549A2 (pt) derivados de pirimidina como inibidores de btk e usos dos mesmos
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
UY34420A (es) ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos"
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
BR112017013012A2 (pt) compostos de indenil, composições farmacêuticas e usos médicos destes
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
MX2015009330A (es) Reordenamiento del virus de influenza.
MX373197B (es) Formulaciones estables de undecanoato de testosterona.
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: ABBVIE STEMCENTRX LLC

FG Grant or registration